Patents by Inventor Samit Satish Mehta
Samit Satish Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10278946Abstract: The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.Type: GrantFiled: February 28, 2018Date of Patent: May 7, 2019Assignee: EMCURE PHARMACEUTICALS LIMITEDInventors: Hiren Pravinbhai Patel, Haresh Ishwarbhai Patel, Arpan Suresh Chudasama, Neha Manubhai Patel, Deepak Pragjibhai Gondaliya, Mukund Keshav Gurjar, Samit Satish Mehta
-
Publication number: 20180311203Abstract: The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel, and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.Type: ApplicationFiled: January 7, 2016Publication date: November 1, 2018Inventors: Hiren Pravinbhai PATEL, Haresh Ishwarbhai PATEL, Arpan Suresh CHUDASAMA, Neha Manubhai PATEL, Deepak Pragjibhai GONDALIYA, Mukund Keshav GURJAR, Samit Satish MEHTA
-
Publication number: 20180185323Abstract: The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.Type: ApplicationFiled: February 28, 2018Publication date: July 5, 2018Inventors: Hiren Pravinbhai PATEL, Haresh lshwarbhai PATEL, Arpan Suresh CHUDASAMA, Neha Manubhai PATEL, Deepak Pragjibhai GONDALIYA, Mukund Keshav GURJAR, Samit Satish MEHTA
-
Patent number: 9919993Abstract: The present invention provides a process for preparation of {(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl)phenyl-3,7-dimethyl-nona-2,4,6,8}tetraenoate, an acitretin intermediate of formula (VI) with trans isomer ?97%, comprising of reacting 3-formyl-crotonic acid butyl ester of formula (V), substantially free of impurities, with 5-(4-methoxy-2,3,6-trimethylphenyl)-3-methyl-penta-2,4-diene-1-triphenyl phosphonium bromide of formula (IV) and isolating resultant compound of formula (VI), treating the filtrate with iodine for isomerization of the undesired cis intermediate and finally obtaining acitretin (I), with desired trans isomer ?97%.Type: GrantFiled: September 8, 2015Date of Patent: March 20, 2018Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Shashikant Gangaram Joshi, Sachin Arvind Badhe, Mangesh Gorakhanath Kamble, Samit Satish Mehta
-
Publication number: 20170275229Abstract: The present invention provides a process for preparation of {(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl)phenyl-3,7-dimethyl-nona-2,4,6,8}tetraenoate, an acitretin intermediate of formula (VI) with trans isomer?97%, comprising of reacting 3-formyl-crotonic acid butyl ester of formula (V), substantially free of impurities, with 5-(4-methoxy-2,3,6-trimethylphenyl)-3-methyl-penta-2,4-diene-1-triphenyl phosphonium bromide of formula (IV) and isolating resultant compound of formula (VI), treating the filtrate with iodine for isomerization of the undesired cis intermediate and finally obtaining acitretin (I), with desired trans isomer?97%.Type: ApplicationFiled: September 8, 2015Publication date: September 28, 2017Inventors: Gurjar Mukund KESHAV, Shashikant Gangaram JOSHI, Sachin Arvind BADHE, Mangesh GORAKHANATH KAMBLE, Samit Satish MEHTA
-
Patent number: 9522924Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.Type: GrantFiled: August 22, 2016Date of Patent: December 20, 2016Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Golakchandra Sudarshan Maikap, Rajendra Dagesing Mahale, Tushar Pandurang Khaladkar, Ashok Tukaram Chaudhari, Sanjay Shankar Pawar, Vijay Keshav Kalhapure, Samit Satish Mehta
-
Publication number: 20160355529Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.Type: ApplicationFiled: August 22, 2016Publication date: December 8, 2016Inventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Golakchandra Sudarshan Maikap, Rajendra Dagesing Mahale, Tushar Pandurang Khaladkar, Ashok Tukaram Chaudhari, Sanjay Shankar Pawar, Vijay Keshav Kalhapure, Samit Satish Mehta
-
Patent number: 9480681Abstract: Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.Type: GrantFiled: September 5, 2012Date of Patent: November 1, 2016Assignee: Emcure Pharmaceuticals LimitedInventors: Jitendra Mohansingh Baweja, Manoj Kumar Thottasseri, Sandip Tanaji Salunkhe, Mukund Keshav Gurjar, Samit Satish Mehta
-
Publication number: 20160311810Abstract: The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).Type: ApplicationFiled: June 28, 2016Publication date: October 27, 2016Inventors: Mukund Keshav Gurjar, Swapnil Panditrao Sonawane, Golakchandra Sudarshan Maikap, Gulabrao Dagadu Patil, Shivnath Bhaupatil Shinde, Pankaj Shalikrao, Samit Satish Mehta
-
Patent number: 9475799Abstract: The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).Type: GrantFiled: June 28, 2016Date of Patent: October 25, 2016Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Swapnil Panditrao Sonawane, Golakchandra Sudarshan Maikap, Gulabrao Dagadu Patil, Shivnath Bhaupatil Shinde, Pankaj Shalikrao, Samit Satish Mehta
-
Patent number: 9447094Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.Type: GrantFiled: May 4, 2015Date of Patent: September 20, 2016Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Golakchandra Sudarshan Maikap, Rajendra Dagesing Mahale, Tushar Pandurang Khaladkar, Ashok Tukaram Chaudhari, Sanjay Shankar Pawar, Vijay Keshav Kalhapure, Samit Satish Mehta
-
Patent number: 9403809Abstract: The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).Type: GrantFiled: December 21, 2012Date of Patent: August 2, 2016Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Swapnil Panditrao Sonawane, Golakchandra Sudarshan Maikap, Gulabrao Dagadu Patil, Shivnath Bhaupatil Shinde, Pankaj Shalikrao, Samit Satish Mehta
-
Publication number: 20150232467Abstract: The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R1, R2 and R3 are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R1 is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R2 is methyl, methoxy and hydrogen, and R3 is methyl and hydrogen.Type: ApplicationFiled: May 4, 2015Publication date: August 20, 2015Inventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Golakchandra Sudarshan Maikap, Rajendra Dagesing Mahale, Tushar Pandurang Khaladkar, Ashok Tukaram Chaudhari, Sanjay Shankar Pawar, Vijay Keshav Kalhapure, Samit Satish Mehta
-
Patent number: 9006453Abstract: The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.Type: GrantFiled: August 27, 2012Date of Patent: April 14, 2015Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Neelakandan Kaliaperumal, Pravin Prabhakar Ahirrao, Raghuramireddy Baireddy, Prabhakaran Balasubramanian, Srinivas Nandala, Prasad Pandurang Panchabhai, Samit Satish Mehta
-
Publication number: 20150045554Abstract: The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).Type: ApplicationFiled: December 21, 2012Publication date: February 12, 2015Inventors: Mukund Keshav Gurjar, Swapnil Panditrao Sonawane, Golakchandra Sudarshan Maikap, Gulabrao Dagadu Patil, Shivnath Bhaupatil Shinde, Pankaj Shalikrao, Samit Satish Mehta
-
Patent number: 8952155Abstract: Disclosed is process for the preparation of a key Rilpivirine intermediate namely, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride (II) by a process comprising reaction of the tetrafluoroborate salt of the diazonium ion of 2,6-dimethyl-4-amino-1-carboxybenzyl phenylamine (VI) with acrylonitrile in presence of palladium acetate, followed by treatment with an acid and its subsequent conversion to the hydrochloride salt (II), wherein the undesired Z isomer is less than 0.5% and provides Rilpivirine hydrochloride having Z isomer less than 0.1%.Type: GrantFiled: April 9, 2012Date of Patent: February 10, 2015Assignee: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Golakchandra Sudarshan Maikap, Shashikant Gangaram Joshi, Sachin Aravind Badhe, Samit Satish Mehta
-
Patent number: 8921596Abstract: The present invention provides a simple and efficient method for synthesis of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine hydrochloride. The process involves the treatment of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine free base with hydrochloric acid in water followed by isolation of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine hydrochloride of desired purity.Type: GrantFiled: March 15, 2011Date of Patent: December 30, 2014Assignee: Emcure Pharmaceuticals, Ltd.Inventors: Mukund Keshav Gurjar, Narendra Kumar Tripathy, Sandeep Anilrao Kotharkar, Pradip Nana Patil, Samit Satish Mehta
-
Publication number: 20140341990Abstract: Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.Type: ApplicationFiled: September 5, 2012Publication date: November 20, 2014Applicant: EMCURE PHARMACEUTICALS LIMITEDInventors: Jitendra Mohansingh Baweja, Manoj Kumar Thottasseri, Sandip Tanaji Salunkhe, Mukund Keshav Gurjar, Samit Satish Mehta
-
Publication number: 20140275538Abstract: Disclosed is process for the preparation of a key Rilpivirine intermediate namely, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride (II) by a process comprising reaction of the tetrafluoroborate salt of the diazonium ion of 2,6-dimethyl-4-amino-1-carboxybenzyl phenylamine (VI) with acrylonitrile in presence of palladium acetate, followed by treatment with an acid and its subsequent conversion to the hydrochloride salt (II), wherein the undesired Z isomer is less than 0.5% and provides Rilpivirine hydrochloride having Z isomer less than 0.1%.Type: ApplicationFiled: April 9, 2012Publication date: September 18, 2014Applicant: Emcure Pharmaceuticals LimitedInventors: Mukund Keshav Gurjar, Golakchandra Sudarshan Maikap, Shashikant Gangaram Joshi, Sachin Aravind Badhe, Samit Satish Mehta
-
Publication number: 20140228582Abstract: The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.Type: ApplicationFiled: August 27, 2012Publication date: August 14, 2014Applicant: EMCURE PHARMACEUTICALS LIMITEDInventors: Mukund Keshav Gurjar, Neelakandan Kaliaperumal, Pravin Prabhakar Ahirrao, Raghuramireddy Baireddy, Prabhakaran Balasubramanian, Srinivas Nandala, Prasad Pandurang Panchabhai, Samit Satish Mehta